Provider review
Trava Health Review: A Named Lab, an FDA Approval That Does Not Exist
Trava Health's headline assurance is that its GLP-1s are “quality tested in the USA by FDA labs”, and its FAQ names the lab, Eagle Analytics in Houston, as “an FDA approved lab”. FDA does not approve laboratories — it approves drugs. Naming the lab is a real step; publishing nothing from it is not. No certificate of analysis, potency result or purity result is on the site.
Some links on this site are affiliate links, and we may earn a commission. How we’re paid
Visit Trava HealthOf Trava Health’s 5 dated product claims documented below, 2 are consistent with the cited evidence. Comparable upfront pricing is not established here. A matching claim does not mean the compounded product was tested or FDA-approved.
Names its testing lab and its pharmacies, then calls the lab “FDA approved”, an approval that does not exist, and publishes no test result of any kind.
Correction, August 2026
This review previously said: “$118 is a quarterly package divided, not a monthly rate — the site shows “$117.96 / monthly” and “Save $87.92 with Our Quarterly Package”, and the cents are the giveaway.”
That was wrong. The cents were read as evidence of a divided package total. They are not evidence of anything on their own, and the arithmetic that would have settled it was never done: three monthly payments minus the stated quarterly saving, divided by three, gives a different and lower figure — the one Trava prints on its own home page card. A number's shape is not a source. Doing the division would have taken one line.
It now says: The advertised figure is the monthly rate, printed as "/ monthly" on the product page. The quarterly package is the cheaper option, and its effective monthly rate is the lower figure on the home page card. What is genuinely inconsistent is that the semaglutide and tirzepatide cards use "As Low As" to mean the quarterly rate and the monthly rate respectively.
Worth trusting if
- You have obtained a certificate of analysis directly and independently of the site
- You are buying the quarterly package and have compared the package total rather than the monthly figure
Be skeptical if
- You are relying on “tested in the USA by FDA labs” as a quality assurance
- You want any published test result at all
- You want semaglutide or tirzepatide without added B12
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Compounded
Phase 3 trials
Named
None found
Provenance
Products reviewed at Trava Health
These evidence cards classify the treatments evaluated in this review. Confirm the exact medicine and formulation proposed for your prescription with the care team.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- Compounded Semaglutide — $117.96 is the monthly rate at the starting 0.25 mg dose, printed as such on the semaglutide page; the price rises with each dose, to $187.96 a month at 2.5 mg. At the starting dose the quarterly package takes $87.92 off three months, which works out at $88.65 a month. That is the figure on Trava's home page card, and the banner's “GLP-1's as low as $89” is the same number rounded. Tirzepatide is $178.98 a month at 2.5 mg, rising to $319.98 at 15 mg, with $94.96 off a quarter at the starting dose, so about $147.33 a month on the package. Its card advertises the monthly figure as "As Low As", while the semaglutide card advertises the quarterly one, so the same two words mean different things in the same row.
- Sermorelin — $157.91 a month on the product page, with $125.82 off the quarterly package, which works out at $115.97 a month. One strength is listed. The home page card shows the monthly rate as "As Low As", and the products listing shows the quarterly one.
- NAD+ Injection — $158.93 a month on the product page, with $127.86 off the quarterly package, which works out at $116.31 a month. The home page card prints "As Low As $127.86", which is the quarterly saving, not a price.
- NAD+ Nasal Spray — $157.91 a month on the product page, with $125.82 off the quarterly package, which works out at $115.97 a month. The home page card prints "As Low As $125.82", which is the quarterly saving, not a price.
- Glutathione Injection — $124.71 a month on the product page, with $99.77 off the quarterly package, which works out at $91.45 a month.
Evidence
Has the molecule been tested for what it is sold for?
Each row summarizes human evidence for the molecule and the use being advertised. Results apply to the product, dose, population and outcome studied; they do not establish that this provider’s preparation or program produces the same results. Compounded drugs are not FDA-approved. Evidence for one use should not be assumed to support another.
1
Products with human evidence
For the advertised use, out of 5 products reviewed here. The evidence concerns the molecule, not Trava Health's service.
1
Registry records cited
Distinct ClinicalTrials.gov records cited across the reviewed products. Registration alone does not establish that a treatment works.
The comparison
What they claim, against what the trials show
Each claim below is quoted word for word from Trava Health’s own page. Tap a row to see the quote, the trials behind it, and why it got that verdict.
Compounded SemaglutideSemaglutide · Compounded (503A)No trial supports this claim
“Quality tested in the USA by FDA labs”
Read on the Trava Health site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Semaglutide 2.4 mg over 68 weeks — the trial record for the FDA-approved product. It says nothing about how any compounded preparation was made or tested.
Trava's website publishes no certificate of analysis, no potency or purity result and no third-party report. It names one testing laboratory, in its FAQ: “All third party testing is does by Eagle Analytics Labratory. Eagle Analytics is an FDA approved lab that is located in houston Texas.” Nothing from that laboratory is published.
Graded unsupported. “Tested in the USA by FDA labs” reads as FDA having tested the product, and the FAQ spells out what Trava means: its testing laboratory, Eagle Analytics, is “an FDA approved lab”. That regulatory status does not exist. FDA approves drugs and clears devices; it does not approve, license, certify or accredit laboratories. Clinical laboratories operate under CLIA and state regulation, and compounded drugs are not FDA-approved at all, which Trava's own footer says. The claim is attached to testing, the one assurance a compounded-drug buyer is actually after, and nothing stands behind it on the site: the laboratory is named, but no certificate, potency result or purity result is published.1
SermorelinSermorelin · Compounded (503A)Claim matches the trials
“Sermorelin is a synthetic peptide that stimulates the body’s natural release of growth hormone by acting on the pituitary gland. It functions by signaling the body to produce its own growth hormone rather than supplying growth hormone directly. This mechanism supports the body’s existing hormone signaling pathways. […] Compounded sermorelin has not been reviewed or approved by the FDA.”
Read on the Trava Health site, September 2026
No trial for this use
What the trials show for Sermorelin
As of August 2026, a PubMed search for sermorelin filtered to the randomized-controlled-trial publication type returned 19 records, the most recent published in 2005. Every one measures growth hormone secretion, growth in children, or the response to a diagnostic challenge. None tests energy, recovery, body composition or wellness in healthy adults. A parallel ClinicalTrials.gov search returned 27 studies; the two closest to wellness use are both phase 2 and both terminated, at 13 and 5 participants.
The page describes the mechanism and stops there. Prompting the pituitary to release its own growth hormone is exactly what sermorelin's 19 randomized trials measured, and Trava names no outcome beyond it: no recovery, no sleep, no body composition. It also says, on the product page itself, that compounded sermorelin has not been reviewed or approved by the FDA. Nothing here reaches past the evidence.3
NAD+ InjectionNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)Claim matches the trials
“NAD+ (Nicotinamide Adenine Dinucleotide) is a naturally occurring coenzyme found in all living cells and is essential for cellular energy production. It plays a role in metabolic processes by helping convert nutrients into usable cellular energy and supporting various enzymatic reactions in the body. NAD+ levels naturally fluctuate based on factors such as age, stress, and overall metabolic activity. […] Compounded NAD+ products are not evaluated by the FDA.”
Read on the Trava Health site, September 2026
No trial for this use
As of August 2026, a ClinicalTrials.gov intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for nicotinamide adenine dinucleotide combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
Every sentence is about the molecule, and each is settled biochemistry: NAD+ is a coenzyme in every cell, it is central to turning nutrients into usable energy, and its levels vary with age. What Trava does not do is take the next step most sellers take, that an injection of it will restore energy or slow aging, which no completed randomized trial of injected NAD+ has shown. A buyer should read the page for what it is: a description of what NAD+ does in a cell, not a promise about what the injection will do for them.4
NAD+ Nasal SprayNAD+ (nicotinamide adenine dinucleotide) · Compounded (503A)Claim reaches past the trials
“NAD+ Nasal Spray is a wellness therapy designed to support cellular health and overall vitality. NAD+ (Nicotinamide Adenine Dinucleotide) is a naturally occurring coenzyme found in every cell of the body and plays a role in cellular energy production and metabolic processes. […] This product has not been evaluated by the FDA for the diagnosis, treatment, cure, or prevention of any disease”
Read on the Trava Health site, September 2026
No trial for this use
As of 10 August 2026, a ClinicalTrials.gov v2 search returns no completed randomized trial of intranasal NAD+ in humans, and no registered study measures nose-to-brain delivery of NAD+. A PubMed search for "nicotinamide adenine dinucleotide" combined with intranasal or nasal, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature on raising NAD+ concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route.
The biochemistry is right, and it is the same restrained description as the injection page. The first sentence goes one step further: the spray is "designed to support cellular health and overall vitality". That is an outcome for the person using it, and no randomized trial of NAD+ given through the nose has measured cellular health, vitality or anything else. The claim is mild and hedged, and it still promises more than any study of this route has shown.4
Glutathione InjectionGlutathione · Compounded (503A)Claim reaches past the trials
“Glutathione is a naturally occurring antioxidant produced in the body that plays a role in cellular health and oxidative stress support. It is involved in processes related to detoxification and helps protect cells from damage caused by free radicals. Injectable glutathione may be used as part of a wellness program designed to support overall health and antioxidant balance under the supervision of a licensed healthcare provider.”
Read on the Trava Health site, September 2026
No trial for this use
What the trials show for Glutathione
As of August 2026, a PubMed search for glutathione in title or abstract, combined with an injected route and with skin, detoxification, fatigue or energy, restricted to the randomized-controlled-trial publication type, returned seven records. Not one tests injected glutathione on its own for any of those outcomes. On ClinicalTrials.gov, 268 studies list glutathione as an intervention; restricting to injected routes returns three, in mantle-cell lymphoma, acute liver failure and pneumonia.
The first two sentences describe the body's own glutathione, and they are accurate: it is an antioxidant, it takes part in detoxification, and it protects cells from free-radical damage. The third moves from the molecule to the product, saying injected glutathione may help "support overall health and antioxidant balance". No randomized trial of injected glutathione on its own has measured either. The hedge is real, and the page is more careful than most, but the benefit it points to is the one nobody has tested.5
Dispensing chain
Who actually fills your prescription
- Optimal Balanced Pharmacy
- VialsRx
Read the full account
Trava's FAQ names two pharmacies: asked which pharmacies fill orders, it answers “Optimal Balanced Pharmacy & Vials RX”, and it says peptides ship from either one. No regulatory category — 503A or 503B — is stated. The footer's supply-chain statement is correct: Trava “works with state-licensed pharmacies that compound and dispense products consistent with state and federal law and applicable safety and sterility standards set by the United States Pharmacopoeia”, and compounded medications “are not FDA approved and have not been evaluated for safety and effectiveness by the FDA”. The same FAQ says Trava's GLP-1s contain B12 (“Is Trava's GLP-1 pure? No… our products contain B12”), so the preparation is not plain semaglutide or tirzepatide.
Read on the Trava Health site, September 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Not established in this source review
Certificate of analysis readable
A readable lot report was not verified here
Read the full testing account
Testing is the site's headline assurance and nothing published supports it. The FAQ names the laboratory, Eagle Analytics in Houston, but no certificate of analysis, potency result, purity result or third-party report is published or offered. The FAQ calls that laboratory “an FDA approved lab”, an approval FDA does not issue.
Read on the Trava Health site, September 2026.
Licensing
Licensed to dispense, and where
Coverage
No state list or set of exclusions is published on the public pages.
Read the full licensing claim
Prescribing is through a named partner group, Wasef Health Partners, with five physicians named individually: Dr. Michael Wasef, MD, Dr. David Wasef, MD, Dr. Andrew Sakla, DO, and Dr. James Teet, DO (internal medicine), and Dr. Constantin Chikando, MD (emergency medicine). Naming them is what makes them checkable. The providers page also says the medical team comes from a partnership with Beluga Health and Bask Health.
Read on the Trava Health site, September 2026.
Regulatory
The FDA warning letter
No FDA warning letter found
We did this ourselves
What happens when you sign up with Trava Health
We went through Trava Health’s signup ourselves in August 2026: the steps, when a price first appears, and what it asks you for. We stopped at checkout, so nothing here is a prescription or a medical result.
- Press "Take The Free Quiz" or "Start your consult". Every product price is already public.
- Say what you are hoping to achieve, from five options, choosing as many as apply.
- Enter an email address.
- "Create an account" — first name, last name and a password of at least eight characters with an uppercase letter, a number and a symbol, plus a terms and telehealth consent box.
- This walk stopped there. We do not create password-protected accounts, so nothing past that screen was seen.
- Both GLP-1s are priced before any question. At the starting dose semaglutide is $117.96 a month, or $88.65 a month on the quarterly package. Tirzepatide is $178.98 a month, or about $147.33 on the quarterly.
- The dose menus are published on the product pages, semaglutide 0.25 to 2.5 mg and tirzepatide 2.5 to 15 mg, and choosing a dose changes the price on the page. Each step up costs more.
- The page called "Our Transparent Pricing" sets a monthly plan against a quarterly one — "Save up to 33%" — and says price depends on the prescribed strength, but prints no figure for either plan.
- The home page says the medication is "quality tested in the USA by FDA labs". The footer on the same page says compounded medications "are not FDA approved" and that Trava works with "state-licensed pharmacies". The footer is right.
- Five physicians are named under a partner group, Wasef Health Partners.
- The visit demands a password-protected account at the third screen, before a single medical question.
Trava Health support
- Phone
- 1-855-872-8279
Assessment
What holds up, and what does not
- At the starting dose, the effective price is toward the cheap end of the compounded semaglutide market.
- Every dose's price is on the product page, so the cost of stepping up is visible before you start.
- Its newer sermorelin and NAD+ injection pages describe what the molecule does and promise no outcome, and each states that the compounded product is not FDA-reviewed.
Show 5 more
- It names its two pharmacies and its testing laboratory in the FAQ.
- The quarterly package's saving is stated in dollars against the monthly figure, so the two are directly comparable.
- Both semaglutide and tirzepatide are priced on public pages rather than behind an intake, and the monthly rate is printed as a monthly rate.
- It names its clinical partner group, Wasef Health Partners, and five individual physicians.
- Its footer disclosure is correct where the headline is not: compounded medications "are not FDA approved and have not been evaluated for safety and effectiveness by the FDA", and Trava "works with state-licensed pharmacies" meeting United States Pharmacopoeia standards.
- The FAQ calls its testing laboratory "an FDA approved lab", a regulatory category that does not exist. FDA approves drugs and clears devices; it does not approve, license or accredit laboratories.
- Testing is the headline assurance and nothing is published behind it — no certificate of analysis, no potency or purity result, no third-party report.
- No regulatory category, 503A or 503B, is stated for either pharmacy.
Show 8 more
- Both GLP-1s contain B12, which appears only in the FAQ, not on the product pages.
- The headline prices are the lowest dose; the top semaglutide dose costs more than half again as much.
- The home page cards use "As Low As" to mean different things: the quarterly effective rate on semaglutide, the monthly rate on tirzepatide, sermorelin and glutathione, and on the two NAD+ cards the dollar saving on the quarterly package, which is not a price at all.
- The NAD+ nasal spray and glutathione pages point to outcomes, vitality and antioxidant balance, that no trial of those routes has measured.
- The page headed "Our Transparent Pricing" describes a monthly and a quarterly plan and carries no figure for either.
- The site's own footer contradicts its own headline on what FDA does, and the headline is the sentence in the larger type.
- No state coverage list or exclusions are published.
- The visit demands a password-protected account at its third screen, before any medical question.
Verdict
The bottom line
The one thing Trava asks you to trust it on — testing — now has a laboratory's name attached, an approval that does not exist, and nothing published behind it. If testing is why you are considering this company, ask for the Eagle Analytics certificate for your lot before you pay.
Opens Trava Health's website. A link is not a recommendation to take anything.
The claim
“Quality tested in the USA by FDA labs”
That line sits under the headline on Trava's home page. The FAQ says what it means: “All third party testing is does by Eagle Analytics Labratory. Eagle Analytics is an FDA approved lab that is located in houston Texas and is one of the largest labratories in the nation.”
Full analysis — 8 more sectionsWhy it is wrong · Why this one is worse than the others · What is published behind it · The trials, and what they cover · What it costs · The newer products · The footer already knows · What this means if you are buying
Why it is wrong
There is no such thing as an FDA-approved laboratory.
FDA approves drugs and clears devices. Clinical laboratories in the United States are regulated under CLIA — the Clinical Laboratory Improvement Amendments — and by state authorities. Compounding pharmacies are licensed by state boards of pharmacy. FDA neither approves nor licenses nor accredits any of them.
And compounded drugs are not FDA-approved either, which is the further problem: the phrase attaches FDA's name to a product category FDA has specifically not reviewed. "Tested by FDA labs" goes further still, and reads as though FDA itself did the testing.
Why this one is worse than the others
These phrases need different checks. GOAL MD’s "FDA-monitored 503A/B pharmacies" refers broadly to oversight that does exist, but does not identify a facility or establish product approval. 6 OrderlyMeds was cited by FDA for saying "FDA-licensed pharmacy". Trava’s "FDA approved lab" is a separate claim about laboratory status; an inspection or registration does not substantiate that claim.
The difference is what the phrase is doing. The others describe who makes the drug. This one describes testing — and testing is the specific assurance a person buying a compounded injectable is trying to obtain, because it is the thing that separates a properly made preparation from an improperly made one.
What is published behind it
A name, and nothing else.
Trava deserves credit for naming its laboratory, and its FAQ also names the two pharmacies that fill orders, Optimal Balanced Pharmacy and VialsRx. That makes the supply chain checkable in a way many sellers' is not.
What is missing is the testing itself. No certificate of analysis. No potency result. No purity result. No batch or lot record. A lab's name tells you who Trava says does the testing; it does not tell you what any test found.
One more thing the FAQ discloses that the product pages do not: Trava's GLP-1s contain B12. Asked "Is Trava's GLP-1 pure?", the FAQ answers "No… our products contain B12."
The trials, and what they cover
Semaglutide has substantial phase 3 weight-loss evidence. 1 Tirzepatide does too. 2
Those trials tested FDA-approved finished products made to registered specifications under manufacturing oversight. They establish what the molecule does when it is properly made. They say nothing about how any particular compounded preparation was made, what is in the vial, or whether it was tested — which is exactly the gap a testing claim is supposed to fill.
What it costs
Everything is priced in public, which is worth saying first — no intake, no email wall. As of September 2026, at the starting dose:
- Semaglutide — $117.96 a month, or $87.92 off a quarter, which is $88.65 a month on the package
- Tirzepatide — $178.98 a month, or $94.96 off a quarter, about $147.33 a month on the package
An earlier version of this review said the advertised figure was a quarterly total divided. It is not; it is the monthly rate, and the correction is at the top of this page.
The price rises with the dose, and every rung is on the product page: semaglutide reaches $187.96 a month at 2.5 mg, tirzepatide $319.98 at 15 mg. The banner's “as low as $89” is the starting-dose semaglutide price on the quarterly package, rounded, so it is accurate for the first rung and nowhere else.
The two GLP-1 cards disagree with each other about what "As Low As" means. On semaglutide it is the quarterly rate. On tirzepatide it is the monthly one. Same two words, same row of cards, two different quantities.
And the page titled "Our Transparent Pricing" describes a monthly plan and a quarterly plan, promises "Save up to 33%", explains that price follows the prescribed strength, and prints no number for either.
The newer products
Trava now sells more than GLP-1s. Its catalog adds sermorelin, an NAD+ injection, an NAD+ nasal spray and glutathione, plus several non-peptide products, and each is priced on a public page the same way: a monthly rate, and a dollar saving for the quarterly package.
| Product | Monthly | Quarterly package, per month |
|---|---|---|
| Sermorelin | $157.91 | $115.97 |
| NAD+ injection | $158.93 | $116.31 |
| NAD+ nasal spray | $157.91 | $115.97 |
| Glutathione | $124.71 | $91.45 |
The copy on these pages is more restrained than the headline. The sermorelin page says the peptide "stimulates the body’s natural release of growth hormone", which is what its 19 randomized trials measured, and names no benefit beyond that. 3 The NAD+ injection page describes a coenzyme and its role in a cell, not what an injection will do for you. 4 Each product page also states that the compounded product has not been reviewed or evaluated by the FDA.
Two pages go a step further. The nasal spray is "designed to support cellular health and overall vitality", and no randomized trial of intranasal NAD+ has measured either. 4 Glutathione "may be used" to "support overall health and antioxidant balance", and no randomized trial of injected glutathione on its own has measured that. 5
The home page cards for the two NAD+ products print "As Low As $127.86" and "As Low As $125.82". Those are the dollar savings on the quarterly package, not prices. The products listing gets them right.
The footer already knows
One more thing, and it is the site correcting itself in small type:
"Compounded medications are available by prescription only. They are not FDA approved and have not been evaluated for safety and effectiveness by the FDA. Trava works with state-licensed pharmacies that compound and dispense products consistent with state and federal law and applicable safety and sterility standards set by the United States Pharmacopoeia."
That is right. State boards license compounding pharmacies; USP sets the sterility standards; compounded drugs are not FDA-approved. It sits at the bottom of the same page whose headline says the medication is tested by FDA labs. A company that can write the accurate sentence has no excuse for the headline.
What this means if you are buying
Ask for the Eagle Analytics certificate of analysis for your lot before you pay, and ask which of the two pharmacies compounded it. If those are not forthcoming, the testing claim on the homepage should be treated as marketing copy rather than as information. On price, read the figure for the dose you expect to reach, not the starting rung the banner quotes.
Questions
Frequently asked questions
What is an FDA-approved lab?
Nothing — there is no such category. FDA approves drugs and clears medical devices. Clinical laboratories are regulated under CLIA and by state authorities, and compounding pharmacies are licensed by state boards of pharmacy. Compounded drugs are not FDA-approved either.
Does Trava publish any test results?
No. Testing is its headline claim, and its FAQ names the laboratory, Eagle Analytics in Houston, but no certificate of analysis, potency result, purity result or third-party report appears anywhere on the site.
Is $117.96 the monthly price?
Yes. The semaglutide page prints its monthly figure as the monthly rate, and the quarterly package is the cheaper option: it takes a fixed amount off three of those months, which works out lower per month and is the number Trava's own home page card advertises for semaglutide. It is the price at the starting dose only: each higher dose costs more, and every rung is priced on the product page. The tirzepatide card uses “As Low As” to mean the monthly rate while the semaglutide card uses it to mean the quarterly one.
Compare
Others selling what Trava Health sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Ranked
The lists Trava Health is on
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Trava Health's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 6 sources
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
- US National Library of Medicine (2026). PubMed search: sermorelin AND randomized controlled trial[pt] — 19 records, most recent 2005; ClinicalTrials.gov intervention "sermorelin" — 27 studies. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=sermorelin+AND+randomized+controlled+trial%5Bpt%5D
- US National Library of Medicine (2026). ClinicalTrials.gov v2 and PubMed searches for injected and intranasal NAD+ in humans: no completed randomised trial supporting a restoration-of-function claim, no registered study of nose-to-brain NAD+ delivery, and zero randomised-controlled-trial publications for nicotinamide adenine dinucleotide combined with injection, subcutaneous or nasal administration. Run 2026-08-10.. ClinicalTrials.gov / PubMed. https://clinicaltrials.gov/search?intr=NAD%2B
- US National Library of Medicine (2026). PubMed search: glutathione[tiab] AND injected route AND (skin OR detoxification OR fatigue OR energy) AND randomized controlled trial[pt] — 7 records, none testing injected glutathione alone; ClinicalTrials.gov injected-route glutathione — 3 studies, in lymphoma, acute liver failure and pneumonia. PubMed / ClinicalTrials.gov. https://pubmed.ncbi.nlm.nih.gov/?term=glutathione%5Btiab%5D+AND+randomized+controlled+trial%5Bpt%5D
- US Food and Drug Administration (2026). Compounding and the FDA: Questions and Answers. FDA; accessed November 3, 2026. https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.